Evidence map›Paper›PMID 36729144›Full record

ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2023

National trends in osteoporosis medication use among Medicare beneficiaries with and without Alzheimer's disease/related dementias.

Peyton Armstrong, Yong-Fang Kuo, Peter Cram, Jordan Westra, Mukaila A Raji

Abstract read
PubMed Publisher
In one paragraph

Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Peyton ArmstrongJohn Sealy School of Medicine, University of Texas Medical Branch, Galveston, TX, USA. pearmstr@utmb.edu.ORCID http://orcid.org/0000-0002-1100-0183
Yong-Fang KuoJohn Sealy School of Medicine, University of Texas Medical Branch, Galveston, TX, USA.
Peter CramJohn Sealy School of Medicine, University of Texas Medical Branch, Galveston, TX, USA.
Jordan WestraSchool of Public and Population Health, University of Texas Medical Branch, Galveston, TX, USA.
Mukaila A RajiJohn Sealy School of Medicine, University of Texas Medical Branch, Galveston, TX, USA. muraji@utmb.edu.
John Sealy Hospital · USThe University of Texas Medical Branch at Galveston · US

Funding

Pattern, Variation and Outcomes of Opioid Prescription in Older AdultsR01DA039192 · NIDA · UNIVERSITY OF TEXAS MED BR GALVESTON · PI KUO, YONG-FANG, RAJI, MUKAILA A · 2016 to 2023
$3.1M
National Institute on Drug Abuse R01DA039192
6 · The paper itself

Abstract

backgroundOsteoporotic fractures  are a leading cause of disability and premature death in the elderly. Patients with Alzheimer's and related dementia (ADRD) have high rates of osteoporosis (OP) and substantial risk of osteoporotic fractures. Yet research is sparse on trends and predictors of OP medication use in ADRD.

methodsMedicare beneficiaries with OP aged ≥ 67 years have Medicare parts A/B/D without HMO from 2016 to 2018. Our outcome was receipt of OP medications in 2018. A multivariable logistic regression assessed association between ADRD and OP drug prescribing, adjusted for age, sex, race, region, Medicare entitlement, dual Medicaid eligibility, chronic conditions, number of provider visits/hospitalizations, and nursing home (NH) resident status. Age/ADRD and NH residency/ADRD interactions were tested.

resultsOur sample consisted of 47,871 people with OP and ADRD and 201,840 with OP without ADRD. OP drug use was 38.6% in ADRD patients vs. 52.7% in non-ADRD. After adjustment for demographics, chronic conditions, and previous hospitalizations/physician visits, the OR for OP drug in ADRD vs. non-ADRD was 0.85 (95% CI: 0.83-0.87). NH residents had lower odds for OP medication (OR: 0.61, 95% CI: 0.58-0.64). There were significant interactions between ADRD and age, and between ADRD and NH residency. The OR for OP drug use associated with ADRD was 0.88 (95% CI: 0.86-0.90) among community-dwelling elders and 0.66 (95% CI: 0.64-0.69) among NH residents.

conclusionsADRD patients received OP drugs at a lower rate than their non-ADRD counterparts. More research is needed on when to prescribe or deprescribe OP drugs in the context of different ADRD severity, patient preferences, remaining life expectancy, and time-to-benefit from OP drugs.

Indexed as

Alzheimer DiseaseOsteoporosisOsteoporotic FracturesAgedChronic DiseaseHumansMedicareRetrospective StudiesUnited StatesDementiaFragility fractureGeriatric medicineNursing homeOsteoporosis

Identifiers

PMID36729144
OpenAlexW4318913187

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.